Topic: Health services, long-term care and technology
Plain-language summary
The costs of AD were estimated to be from around 91 billion RMB in 2010 to 332 billion in 2050. Most of the current burden was related to private caregivers paid by families. With the percentage of patients being treated changing from 5% to 40%, costs were estimated to double. This was related to more hospitalisations and more use of care facilities, while the burden for families would decrease. A high economic burden related to AD is predicted. The burden would be driven mainly by indirect costs related to the social support of the patients. Investment in improving awareness and care of AD patients is needed and worth it.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Clay, E., Zhou, J., Yi, Z.-M., Zhai, S., & Toumi, M. (2019). Economic burden for Alzheimer's disease in China from 2010 to 2050: a modelling study. Journal of market access & health policy. https://doi.org/10.1080/20016689.2019.1667195
Vancouver
Clay E, Zhou J, Yi Z.-M, Zhai S, Toumi M. Economic burden for Alzheimer's disease in China from 2010 to 2050: a modelling study. Journal of market access & health policy. 2019. doi:10.1080/20016689.2019.1667195. PMID: 31595183.
BibTeX
@article{clay2019-31595183,
author = {Clay, Emilie and Zhou, Junwen and Yi, Zhan-Miao and Zhai, Suodi and Toumi, Mondher},
title = {{Economic burden for Alzheimer's disease in China from 2010 to 2050: a modelling study}},
journal = {Journal of market access \& health policy},
year = {2019},
doi = {10.1080/20016689.2019.1667195},
pmid = {31595183},
url = {https://doi.org/10.1080/20016689.2019.1667195}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The costs of AD were estimated to be from around 91 billion RMB in 2010 to 332 billion in 2050.
- Most of the current burden was related to private caregivers paid by families.
- With the percentage of patients being treated changing from 5% to 40%, costs were estimated to double.
- This was related to more hospitalisations and more use of care facilities, while the burden for families would decrease.
- A high economic burden related to AD is predicted.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 22 of the 56 points we could judge it on, which is 39 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of market access & health policy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31595183) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 22 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 22 of the 56 points we could judge it on is 39 out of 100. |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Costs and economics from nearby years
Also tagged “racial”
265 studies in the library carry the topic tag “racial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 265 tagged studies.